Aktis Oncology (NASDAQ:AKTS) Shares Down 8.2% – Should You Sell?

Aktis Oncology (NASDAQ:AKTS)’s stock price was down 8.2% during mid-day trading on Friday . The stock traded as low as $28.85 and last traded at $28.60. 457,848 shares were traded during trading, an increase of 45% from the average daily volume of 315,832 shares. The stock had previously closed at $31.15.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AKTS shares. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. Raymond James Financial began coverage on shares of Aktis Oncology in a report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Finally, HC Wainwright raised their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Down 5.5%

The stock has a 50-day simple moving average of $20.67.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million during the quarter. Analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.